Fluoxetine and Adult Suicidality Revisited
Authors:
- Charles M. BeasleyCBCharles M. Beasley
- Susan G. BallSBSusan G. Ball
- Mary E. NilssonMNMary E. Nilsson
- John PolzerJPJohn Polzer
- Sitra Tauscher-WisniewskiSTSitra Tauscher-Wisniewski
- John PlewesJPJohn Plewes
- Nayan AcharyaNANayan Acharya
- 1 December 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 27 (6) , 682-686
Abstract
Selective serotonin reuptake inhibitor treatments have been suggested by some to induce emergence of suicidality (ideation and behaviors). The objective of this study was to assess suicidality emergence by adverse event and rating scale data in the largest available, adult, major depression, double-blind, placebo-controlled, fluoxetine trial database (18 trials). Adverse event reports and comments for patients (fluoxetine, n = 2200; placebo, n = 1551) were searched for suicide-related events that were then classified into Food and Drug Administration categories. For 16 trials, suicidality was also examined by Hamilton Depression Scale item 3 (suicide) scores, and these data were analyzed along with the combination of event-based data and scale-based data. Comparisons between treatments were made for various estimates of worsening (risk) and improvement (benefit) of suicidality. Fluoxetine treatment did not result in greater worsening but was associated with greater improvement and faster resolution of ideation (P < or = 0.05 vs placebo). Data sources were differentially sensitive in detecting changes in suicidal ideation and behaviors. Fluoxetine treatment led to greater benefit rather than risk for suicidality.Keywords
This publication has 13 references indexed in Scilit:
- Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorderPsychological Medicine, 2007
- Suicidality in Pediatric Patients Treated With Antidepressant DrugsArchives of General Psychiatry, 2006
- Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trialsBMJ, 2005
- Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety reviewBMJ, 2005
- Suicide Rates in Clinical Trials of SSRIs, Other Antidepressants, and Placebo: Analysis of FDA ReportsAmerican Journal of Psychiatry, 2003
- Suicide Risk in Placebo-Controlled Studies of Major DepressionAmerican Journal of Psychiatry, 2001
- Dr. Teicher and Associates ReplyAmerican Journal of Psychiatry, 1990
- Emergence of intense suicidal preoccupation during fluoxetine treatmentAmerican Journal of Psychiatry, 1990
- Why do some antidepressants promote suicide?Psychopharmacology, 1986
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986